Biologic Medications for Severe Asthma: Implications for Understanding Pathogenic Heterogeneity and Endotypes.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39586024.
- Also identified by DOI 10.1146/annurev-med-070323-103158 and PMC identifier 12830064.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Asthma is a chronic inflammatory disease of the airways long known for phenotypic heterogeneity. Phenotyping studies in asthma have led to a better characterization of disease pathogenesis, yet further work is needed to pair available treatments with disease endotypes. In this review, the biology of targeted pathways is discussed along with the efficacy of biologic therapies targeting those pathways. Results of asthma clinical trials are included, as well as results of trials in related diseases. This review then analyzes how biologics help to inform the complex immunobiology of asthma and further guide their use while identifying areas for future research.
Medical subject headings
- Asthma
- Anti-Asthmatic Agents
- Biological Products